Key result
Novel biomaterials in extracorporeal life support aim to eliminate the need for systemic anticoagulation.
Answers are grounded in this paper and cite their sources.
A new generation of extracorporeal artificial organ support technologies, collectively known as extracorporeal life support (ECLS) devices, is being developed for diverse applications to include acute support for trauma-induced organ failure, transitional support for bridge to organ transplant, and terminal support for chronic diseases. Across applications, one significant complication limits the use of these life-saving devices: thrombosis, bleeding, and inflammation caused by foreign surface-induced blood interactions. To address this challenge, transdisciplinary scientists and clinicians look to the vascular endothelium as inspiration for development of new biocompatible materials for ECLS. Here, we describe clinically approved and new investigational biomaterial solutions for thrombosis, such as immobilized heparin, nitric oxide-functionalized polymers, "slippery" nonadhesive coatings, and surface endothelialization. We describe how hemocompatible materials could abrogate the use of anticoagulant drugs during ECLS and by doing so radically change treatments in critical care. Additionally, we examine several special considerations for the design of biomaterials for ECLS, including: (1) preserving function of the artificial organ, (2) longevity of use, and (3) multifaceted approaches for the diversity of device functions and applications.
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2020) conducted a review in Thrombosis and inflammation during extracorporeal life support (ECLS). Blood-compatible surfaces and biomaterials was evaluated. Biomaterial solutions for thrombosis in extracorporeal life support, including immobilized heparin and surface endothelialization, aim to abrogate the need for anticoagulant drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: